Portfolio News


January 2015
Sale of Convergence Pharmaceuticals

SV Life Sciences Fund V notes that Biogen Idec (NASDAQ: BIIB) acquired Convergence from its owners, SV Life Sciences and others, for a possible total of $675m - $200m upfront and $475m of milestone based payments.  Convergence Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for chronic pain. 

Biogen Idec Press release


Team - Kate Bingham

⇧ Back to top